選択された蛋白質を分解する複合化合物

Japanese Patent JP4903922

B2

Compounds having an ansamycin anitibiotic, or other moiety which binds to hsp90, coupled to a targeting moiety which binds specifically to a protein, receptor or marker can provide effective targeted delivery of the ansamycin antibiotic leading to the degradation of proteins and death of the targeted cells. These compositions may have different specificity than the ansamycin alone, allowing for a more specific targeting of the therapy, and can be effective in instances where the ansamycin alone has no effect. Thus, these compounds provide an entirely new class of targeted chemotherapy agents with application, depending on the nature of the targeting moiety, to treatment of a variety of different forms of cancer. Such agents can further be used to promote selective degradation of proteins associated with the pathogenesis of others diseases, including antigens associated with autoimmune disorders and pathogenic proteins associated with Alzheimer's disease. Exemplary targeting moieties which may be employed in compounds of the invention include testosterone, estradiol, tamoxifen and wortmannin.

Neil Rosen
Danish Chevskiy, Samuel
Owerferli, Ouasek
Kudaku, Scott, Di.
Sep-Lorengino, Laura

JP54951698A

March 28, 2012

May 14, 1998

Click for automatic bibliography generation  

Sloan-Kettering Institute for Cancer Research

A61K31/58; C07J43/00; A61P35/00; A61P43/00; C07D225/06; C07J17/00

JP8506356A

WO1996006116A1

Biochemical Pharmacology,vol.44,No.11, 1992, p.2117-2122
Journal of Medicinal Chemistry, 1995,Vol.38, No.19, p.3806-3812

Hideto Asamura
Hajime Asamura
Kajiwara Saiko
Yukihiro Ikeda

Previous Patent: αＶβ５仲介血管形成の阻止に有効な方法及び組成物

Next Patent: 衣料用防虫消臭剤